Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2026)

Amneal Pharmaceuticals' Share-based Compensation history runs 9 years deep, the most recent figure standing at $44.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 104.75% year-over-year to $44.3 million in Q1 2026; TTM through Mar 2026 was $44.9 million, a 96.53% increase from a year earlier, with the FY2025 full-year figure at $22.3 million, up 180.16% from the prior year.
• Share-based Compensation rose to $44.3 million in Q1 2026 per AMRX's latest filing, from $321000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $44.3 million in Q1 2026 and bottomed at -$12.6 million in Q4 2024.
• The 5-year median for Share-based Compensation is $6.6 million (2023), against an average of $6.2 million.
• Across the five-year window, Share-based Compensation tumbled 1829.71% in 2022 and jumped 6688.64% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $88000.0 in 2022, then soared by 6688.64% to $6.0 million in 2023, then plunged by 311.01% to -$12.6 million in 2024, then jumped by 102.55% to $321000.0 in 2025, then soared by 13702.18% to $44.3 million in 2026.
• Per Business Quant, the three latest AMRX Share-based Compensation figures stand at $44.3 million (Q1 2026), $321000.0 (Q4 2025), and $6.4 million (Q3 2025).